<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213992</url>
  </required_header>
  <id_info>
    <org_study_id>P-Monofer-PK-CKD-03</org_study_id>
    <secondary_id>P-Monofer-PK-CKD-03</secondary_id>
    <nct_id>NCT01213992</nct_id>
  </id_info>
  <brief_title>Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD</brief_title>
  <acronym>PK-CKD-03</acronym>
  <official_title>Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-Dialysis Dependent Chronic Kidney Disease (PK-CKD-03)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacosmos A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacosmos A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg&#xD;
      and 1000 mg) of Monofer® in patients suffering from Non-dialysis Dependent Chronic Kidney&#xD;
      Disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total serum iron pharmakokinetic parameters</measure>
    <time_frame>30min, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours, 24 hours, 48 hours and 72 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Non-dialysis Dependent Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Monofer® 500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg iron isomaltoside 1000</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monofer® 1000 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 mg iron isomaltoside 1000</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron isomaltoside 1000</intervention_name>
    <description>Single dose of 500 mg administered as a bolus undiluted over 2 min.</description>
    <arm_group_label>Monofer® 500 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron isomaltoside 1000</intervention_name>
    <description>Single dose of 1000 mg infused over 15 min. The infusion is diluted in 100mL 0,9% sodium chloride</description>
    <arm_group_label>Monofer® 1000 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women, aged more than 18 years.&#xD;
&#xD;
          2. Weight above 50 kg.&#xD;
&#xD;
          3. Subjects diagnosed with NDD-CKD with MDRD calculated eGFR between 15-59 mL/min.&#xD;
&#xD;
          4. Hb &lt; 11.0 g/dL.&#xD;
&#xD;
          5. Either or both of the following iron stores indicators below target {Serum ferritin &lt;&#xD;
             100 ug/l and Transferrin saturation (TfS) &lt;20%}.&#xD;
&#xD;
          6. Life expectancy beyond 12 months by Principal Investigator's judgement.&#xD;
&#xD;
          7. Willingness to participate after informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anaemia predominantly caused by factors other than renal impairment or iron deficiency&#xD;
             (according to Principal Investigator s' judgment).&#xD;
&#xD;
          2. Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and&#xD;
             haemosiderosis).&#xD;
&#xD;
          3. Drug hypersensitivity (i.e. previous hypersensitivity to iron dextran or iron mono- or&#xD;
             disaccharide complexes or any excipients of the study drug).&#xD;
&#xD;
          4. Subjects with history of multiple allergies.&#xD;
&#xD;
          5. Decompensated liver cirrhosis and hepatitis (alanine aminotransferase (ALT) &gt; 3 times&#xD;
             upper normal limit).&#xD;
&#xD;
          6. History of Immunocompromise and/or history of Hepatitis B and/or C&#xD;
&#xD;
          7. Active acute or chronic infections (assessed by clinical judgment), supplied with&#xD;
             white blood cells (WBC) and C-reactive protein (CRP).&#xD;
&#xD;
          8. Rheumatoid arthritis with symptoms or signs of active joint inflammation.&#xD;
&#xD;
          9. Pregnancy and nursing (To avoid pregnancy, women have to be postmenopausal (at least&#xD;
             12 months must have elapsed since last menstruation), surgically sterile, or women of&#xD;
             child bearing potential must use one of the following contraceptives during the whole&#xD;
             study period and after the study has ended for at least 5 times plasma biological&#xD;
             half-life of the investigational medicinal product: Contraceptive pills, intrauterine&#xD;
             devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal&#xD;
             implantation, vaginal ring, and transdermal patches).&#xD;
&#xD;
         10. Extensive active bleeding necessitating blood transfusion.&#xD;
&#xD;
         11. Planned elective surgery during the study.&#xD;
&#xD;
         12. Participation in any other clinical study within 3 months prior to screening.&#xD;
&#xD;
         13. Untreated B12 or folate deficiency.&#xD;
&#xD;
         14. Other I.V. or oral iron treatment or blood transfusion within 4 weeks prior to&#xD;
             screening visit.&#xD;
&#xD;
         15. ESA treatment within 8 weeks prior to screening visit.&#xD;
&#xD;
         16. Serum Ferritin &gt; 500 µg/L&#xD;
&#xD;
         17. Any other medical condition that, in the opinion of Principal Investigator, may cause&#xD;
             the subject to be unsuitable for the completion of the study or place the subject at&#xD;
             potential risk from being in the study or interfere with study drug evaluation.&#xD;
             Example, Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled&#xD;
             Diabetes Mellitus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>October 1, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <last_update_submitted>November 13, 2013</last_update_submitted>
  <last_update_submitted_qc>November 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Iron isomaltoside 1000</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

